What SEC filings does PROCEPT BioRobotics Corporation submit to the SEC?

PROCEPT BioRobotics Corporation (PRCT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about PRCT?

A Form 4 for PRCT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from PROCEPT BioRobotics Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for PRCT?

The 10-K is PROCEPT BioRobotics Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all PRCT SEC filings directly on EDGAR?

You can view all historical PROCEPT BioRobotics Corporation filings on the SEC EDGAR company page for PRCT. Each filing card on this page links directly to the original SEC document.

How often does PROCEPT BioRobotics Corporation file with the SEC?

PROCEPT BioRobotics Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling PRCT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

PRCT SEC Filing News — PROCEPT BioRobotics Corporation

Latest SEC filings for PROCEPT BioRobotics Corporation (PRCT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-05.

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower u…

Sector: Healthcare Industry: Medical Devices Market Cap: $1.0B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for PRCT currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

PRCT Filing Activity Snapshot 2026-06-10 — 2026-10-05

Insider Transactions (Form 4)

1 buy vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$498.3K

Wood Larry L (Director, President, CEO) · 2026-08-10

23,900 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for PROCEPT BioRobotics Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 9 compensation award, 3 open-market sale and 1 open-market purchase. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Open-market purchase ×1: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Compensation award Tax / Compensation Filing 2026-10-05

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Mack Michael (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	7,727	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	12,191	—	—

Filing: Form 4 (Insider Transaction) Insider: Mack Michael (Director) Shares: 7,727

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-10

PRCT insider Nouri Alaleh (EVP, CLO, CORP. SEC.) sold 297 shares (~$6.2K)

Nouri Alaleh, listed as EVP, CLO, CORP. SEC. at PROCEPT BioRobotics Corp, reported an open-market sale of 297 PRCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	297	$20.95	$6.2K

Filing: Form 4 (Insider Transaction) Insider: Nouri Alaleh (EVP, CLO, CORP. SEC.) Shares: 297 Est. Value: $6.2K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-10

PRCT insider Templin Barry L (EVP, Chief Technology Officer) sold 373 shares (~$7.8K)

Templin Barry L, listed as EVP, Chief Technology Officer at PROCEPT BioRobotics Corp, reported an open-market sale of 373 PRCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	373	$20.95	$7.8K

Filing: Form 4 (Insider Transaction) Insider: Templin Barry L (EVP, Chief Technology Officer) Shares: 373 Est. Value: $7.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-10

PRCT insider Waters Kevin (EVP, CFO) sold 373 shares (~$7.8K)

Waters Kevin, listed as EVP, CFO at PROCEPT BioRobotics Corp, reported an open-market sale of 373 PRCT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	373	$20.95	$7.8K

Filing: Form 4 (Insider Transaction) Insider: Waters Kevin (EVP, CFO) Shares: 373 Est. Value: $7.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Nouri Alaleh (EVP, CLO, CORP. SEC.) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	22,965	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	31,773	—	—

Filing: Form 4 (Insider Transaction) Insider: Nouri Alaleh (EVP, CLO, CORP. SEC.) Shares: 22,965

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Templin Barry L (EVP, Chief Technology Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	26,246	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	36,312	—	—

Filing: Form 4 (Insider Transaction) Insider: Templin Barry L (EVP, Chief Technology Officer) Shares: 26,246

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Waters Kevin (EVP, CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	29,527	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	40,851	—	—

Filing: Form 4 (Insider Transaction) Insider: Waters Kevin (EVP, CFO) Shares: 29,527

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Sharma Pooja (Chief Strat/Marketing Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	23,622	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	32,681	—	—

Filing: Form 4 (Insider Transaction) Insider: Sharma Pooja (Chief Strat/Marketing Officer) Shares: 23,622

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-10

PRCT insider Wood Larry L (Director, President, CEO) bought 23,900 shares (~$498.3K)

Wood Larry L, listed as Director, President, CEO at PROCEPT BioRobotics Corp, reported an open-market purchase of 23,900 PRCT shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	23,900	$20.85	$498.3K

Filing: Form 4 (Insider Transaction) Insider: Wood Larry L (Director, President, CEO) Shares: 23,900 Est. Value: $498.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Desai Antal Rohit (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,315	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	5,853	—	—

Filing: Form 4 (Insider Transaction) Insider: Desai Antal Rohit (Director) Shares: 3,315

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Dodrill Amy M. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,315	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	5,853	—	—

Filing: Form 4 (Insider Transaction) Insider: Dodrill Amy M. (Director) Shares: 3,315

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Garrett Mary (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,315	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	5,853	—	—

Filing: Form 4 (Insider Transaction) Insider: Garrett Mary (Director) Shares: 3,315

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-10

PRCT insider Form 4 filed for equity award, exercise, or tax withholding

Harris Taylor C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,315	—	—
`A`	Compensation award derivative · Stock Option (Right to Buy)	5,853	—	—

Filing: Form 4 (Insider Transaction) Insider: Harris Taylor C. (Director) Shares: 3,315

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. PROCEPT BioRobotics Corporation has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-09

PRCT Form 144 filed for proposed insider sale by Nouri Alaleh (297 shares) ~$6.2K

Nouri Alaleh filed a Form 144 with the SEC indicating intent to sell PRCT (PROCEPT BioRobotics Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Nouri Alaleh Shares: 297 Est. Value: $6.2K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-09

PRCT Form 144 filed for proposed insider sale by Templin Barry L (373 shares) ~$7.8K

Templin Barry L filed a Form 144 with the SEC indicating intent to sell PRCT (PROCEPT BioRobotics Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Templin Barry L Shares: 373 Est. Value: $7.8K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-09

PRCT Form 144 filed for proposed insider sale by Waters Kevin (373 shares) ~$7.8K

Waters Kevin filed a Form 144 with the SEC indicating intent to sell PRCT (PROCEPT BioRobotics Corp) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Waters Kevin Shares: 373 Est. Value: $7.8K

View on SEC EDGAR → Open Filing Document →

Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for PROCEPT BioRobotics Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-02

PRCT filed 8-K — material company event

PROCEPT BioRobotics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-24

PRCT filed 8-K — material company event

PROCEPT BioRobotics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-04

PRCT filed 8-K — material company event

PROCEPT BioRobotics Corp filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for PROCEPT BioRobotics Corporation.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

PRCT filed Quarterly Report (10-Q)

PROCEPT BioRobotics Corp filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify PROCEPT BioRobotics Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on PRCT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — PRCT SEC Filings

More Tools for PRCT

PRCT Full Stock Analysis PRCT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper PRCT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the PRCT stock analysis page.

PRCT Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer